ArticleBlood advances2021

Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study.

Damien Luque Paz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.